Pharmaceutical Technologist - November 2007 - (Page 13)

// Aitken also offering significant opportunities for growth. Robust growth The five main European markets (France, Germany, Italy, Spain, UK) grew by just a little more than 4% in 2006, reflecting the third year of slowing performance. By contrast, many of the Eastern European countries achieved double-digit growth, as did Latin American markets where sales increased by 12.7%. China’s performance was down on 2005 in the wake of a government anticorruption campaign on physician promotion, but the market nevertheless expanded by 12.3%. In Japan, the impact of biennial price decreases contributed to an overall market decline of 0.4% — a sharp downturn after a strong performance in 2005. One of the fastest growing markets in 2006 was India, where pharmaceutical sales increased by 17.6%. “Last year, India transitioned from a ‘developing’ market to an emerging one, with many multinational pharmaceutical companies tapping into the huge potential it offers,” observes Ray Hill, general manager, global consulting at IMS. “Several factors, including the acceptance of intellectual property rights, a robust economy and the country’s burgeoning healthcare needs, contributed to this accelerated growth.” 2005 levels, and up 35% from the end of 2003. In addition, a promising range of drugs are now in Phase III clinical trials or pre-approval stage, including 95 oncology products, 40 for viral infections and HIV, and 27 for arthritis/pain. More than a quarter Figure 1 World market expands by $42 billion (€29.16 billion), hits $643 billion (€446.14 billion) mark. Growth rate levels at 7%. Total world market Growth over previous year US $ (billion) 500 400 300 200 100 0 1999 2000 2001 2002 2003 2004 2005 2006 4 2 0 Global sales US $ (billion) Total world market (US $) Constant US $ growth 1999 334 14.5 2000 362 11.7 2001 387 11.8 2002 427 10.6 2003 498 10.4 2004 559 8.0 2005 601 6.8 Source: IMS Health, IMS Market Prognosis International, February 2007 Figure 2 Specialist-driven products contribute 62% to growth in 2006. Primary care-driven Specialist-driven Innovation skewed to specialist-driven products Growth in the R&D pipeline remained strong in 2006, especially in the number of products in Phase I and Phase II clinical development. At the end of the year, some 2075 molecules were in development, up 7% from 100 90 80 70 60 50 40 30 20 10 0 % contribution to growth, constant US $ 2000 2001 2002 2003 2004 2005 2006 Source: IMS Health, MIDAS MAT December 2006 % Constant US $ growth 2006 643 7.0 600 16 14 12 10 8 6 www.ptemagazine.com 13 http://www.ptemagazine.com

Table of Contents Feed for the Digital Edition of Pharmaceutical Technologist - November 2007

Pharmaceutical Technologist Contents Editor's Comment News Morpheus Feeling the Pressure Legal Crusaders The Holy-Grail of Start-Up Biotech Special Feature Q&A

Pharmaceutical Technologist - November 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.